WASHINGTON — Genetically engineered salmon that grows twice as fast as the conventional fish appears to be safe, an advisory committee told the Food and Drug Administration on Monday.
But the panel argued that more testing may be needed before the fish is served on the nation's dinner tables.
If the FDA approves the salmon for sale, it will be the first time the government allows such modified animals to be marketed for human consumption. The panel was convened by the agency to look at the science of the fish and make recommendations on its safety and environmental impact.
Ron Stotish, chief executive of AquaBounty, the Massachusetts company that created the salmon, said at Monday's hearing that his company's fish product is safe and environmentally sustainable.
Premium content for only $0.99
For the most comprehensive local coverage, subscribe today.
FDA officials have largely agreed with him, saying that the salmon, which grows twice as fast as its conventional "sisters," is as safe to eat as the traditional variety. But they have not yet decided whether to approve the request.
Critics call the modified salmon a "frankenfish" that could cause allergies in humans and the eventual decimation of the wild salmon population. Representatives from consumer, environmental and food safety groups asked the agency to decline the company's application, saying the fish is untested.
The advisory committee agreed with the FDA that the company has presented compelling evidence that the fish is safe. But members raised several concerns about the data, saying many of the sample sizes were too small and questioning how healthy the fish will be after many years of breeding.
The hearing will continue today, when the agency will hear public comments on labeling. It is possible that consumers would not even know they were eating modified fish. Current FDA regulations require modified foods to be labeled as such only if the food is substantially different from the conventional version, and the agency has said that the modified salmon is essentially the same as the Atlantic salmon.
If approved, the fish could be in grocery stores in two years, the company estimates.
Approval would open the door for a variety of other genetically engineered animals, including a pig that is being developed in Canada or cattle that are resistant to mad cow disease. Each would have to be individually approved by the FDA.
"For future applications out there the sky's the limit," said David Edwards of the Biotechnology Industry Association. "If you can imagine it, scientists can try to do it."
In the case of the salmon, AquaBounty has added a growth hormone from a Chinook salmon that allows the fish to produce growth hormone all year long. The engineers were able to keep the hormone active by using another gene from an eel-like fish called an ocean pout that acts like an on switch for the hormone, according to the company. Conventional salmon produce the growth hormone only some of the time.
In documents released ahead of the hearing, the FDA said there were no biologically relevant differences between the engineered salmon and conventional salmon, and there is a reasonable certainty of no harm from its consumption. FDA scientists said Monday there are very few differences between the modified and conventional fish.
Critics have two main concerns: the safety of the food to humans and the salmon's effect on the environment.
Because the altered fish has never been eaten, they say, it could include dangerous allergens, especially because seafood is highly allergenic. They also worry that the fish will escape and intermingle with the wild salmon population, which is already endangered.
They would grow fast and consume more food to the detriment of the conventional wild salmon, the critics fear.
The FDA tried to allay both of those concerns Monday, saying the fish shouldn't cause any allergies not already found in conventional salmon and that there is little chance they could escape.
Critics speaking at the meeting said they were concerned about the unintended consequences of approval, arguing the FDA is relying on too little data.
AquaBounty CEO Stotish countered that his product has come under more scrutiny than most food.
"This is perhaps the most studied fish in history," he said. "Environmentally this is a very sustainable technology."
The company has several safeguards in place to quell concerns. The fish would be bred female and sterile, though a small percentage might be able to breed. They would be bred in confined pools where the potential for escape would be low.
In its environmental analysis released earlier this month, the FDA agreed with the company that there are enough safeguards in place.